This bill prohibits a health plan that provides coverage for advanced metastatic cancer and associated conditions from requiring an enrollee to fail to successfully respond to a different drug or prove a history of failure of a different drug before providing coverage of a prescription drug approved by the United States Food and Drug Administration.